Alzheimer disease and cerebrovascular pathology: an update
The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Recent epidemiological and clinico-pathologic data suggest overlaps between Alzheimer disease (AD) and cerebrovascular lesions that may magnify the effect of mild AD pathology and promote progression of cognitive decline or even may precede neuronal damage and dementia. Vascular pathology in the aging brain and in AD includes: 1. cerebral amyloid angiopathy (CAA) with an incidence of 82-98% often associated with ApoE epsilon 2 and causing a) cerebral mass hemorrhages (around 70%, mainly in the frontal and parietal lobes), b) multiple or recurrent microhemorrhages (15%), and c) ischemic (micro-)infarcts or lacunes (around 20%). The frequency of these lesions increases with the severity of CAA and shows no correlation with that of senile amyloid plaques. CAA, significantly more frequent in patients with cerebral hemorrhages or infarcts than in aged controls, is an important risk factor for cerebrovascular lesions in AD. 2. Microvascular changes with decreased density and structural abnormalities causing regional metabolic and blood-brain barrier dysfunctions with ensuing neuronal damage. In large autopsy series of demented aged subjects, around 80% show Alzheimer type pathology, 20-40% with additional, often minor vascular lesions, 7-10% "pure" vascular dementia, and 3-5% "mixed" dementia (combination of AD and vascular encephalopathy). AD cases with additional minor cerebrovascular lesions have significantly more frequent histories of hypertension or infarcts than "pure" AD patients. Vascular lesions in AD include cortical microinfarcts, subcortical lacunes, white matter lesions / leukoencephalopathy, small hemorrhages and corticosubcortical infarcts, while in mixed type dementia multiple larger or hemispheral infarcts are more frequent. Small infarcts in AD patients have no essential impact on global cognitive decline which mainly depends on the severity of Alzheimer pathology, but in early stage of AD they may influence and promote the development of dementia. Recent studies showed lower density of plaques and tangles in brains with cerebrovascular lesions, and similar severity of dementia was related to fewer AD lesions in brains with than in those without small vascular lesions. Further studies will help to elucidate the risk factors and impact of cerebrovascular lesions on the development and progression of dementia in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CAA appears in ≈10% to 30% of unselected brain autopsies and 80% to 100% when in the presence of accompanying Alzheimer disease.136”
In the citing paper
“which virtually all individuals with AD and about a third of aged cognitively normal individuals have) [68, 179]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [68]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“of currently used neuropathological diagnostic criteria for AD (Mirra et al., 1991; Braak and Braak, 1991; Hyman, 1998).”
BackgroundMethodMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084 · cited 2×
“…to many authors, MD should be diagnosed only if there are sufficient vascular and degenerative lesions to make each diagnosis independently (Tomlinson et al., 1970; Boller et al., 1989; Erkinjuntti, 1988; Jellinger et al., 1990; Mirra et al., 1991), while others suggest the diagnosis of AD…”
Background15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 1×
“An association between hypertension and AD has been reported in several prospective studies (Skoog et al., 1993, 1996; Hofman et al., 1997; Skoog, 2000; Launer et al., 2000; Meyer et al., 2000; Schmidt et al., 2000; Kivipelto et al., 2001).”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“An association between hypertension and AD has been reported in several prospective studies (Skoog et al., 1993, 1996; Hofman et al., 1997; Skoog, 2000; Launer et al., 2000; Meyer et al., 2000; Schmidt et al., 2000; Kivipelto et al., 2001).”
Background(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338 · cited 2×
“that came to autopsy, but most patients had mixed disease without clear thresholds of pathological features that predicted dementia (Esiri et al., 2001).”
BackgroundChui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201 · cited 2×
“, 1991), while in the ADDTC criteria (Chui et al., 1992), a second cerebrovascular disorder in addition to AD must be shown to”
BackgroundCerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 6×
“…vessels (Claudio, 1996; Farkas et al., 2000) with increase of collagen IV (Kalaria and Pax, 1995) and breakdown of the BBB are considered important factors for disturbances of cerebral metabolism, reduced cerebral blood flow and neural metabolic changes (Shi et al., 2000; Farkas and Luiten, 2001).”
BackgroundInfluentialHofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062 · cited 4×
“Hypertension and hypercholesterinemia, independent of the ApoE genotype have been shown to be risk factors for AD (Hofman et al., 1997; Skoog et al., 1999).”
BackgroundInfluentialClinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
Cited by
Items 401–500 of 681
Current and future diagnostic tools for traumatic brain injury
Brody, D. L., Donald, C. L. M., & Shimony, J. S. (2015) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52892-6.00017-9 · Cited by 25
Latest advances on interventions that may prevent, delay or ameliorate dementia
Wilson, D., Peters, R., Ritchie, K. A., & Ritchie, C. W. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310397636 · Cited by 22
“…of dementia is thought to be one of vascular origin [Lobo et al. 2000] although it is likely that the overlap between these two dementia types is large with the AD pathology occurring alongside vascular damage such as stroke [Barker et al. 2002; Jellinger, 2002; Gold, 1998; Sparks et al. 1995].”
BackgroundIntracranial hemorrhage: frequency, location, and risk factors identified in a TeleStroke network
Backhaus, R., Schlachetzki, F., Rackl, W., Baldaranov, D., Leitzmann, M. F., Hubert, G. J., Müller-Barna, P., Schuierer, G. R., Bogdahn, U., & Boy, S. (2015) · Neuroreport · doi:10.1097/wnr.0000000000000304 · Cited by 21
Alzheimer Disease and Cellular Mechanisms of Memory Storage
Arshavsky, Y. I. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000043 · Cited by 20
“A common property of all nongenetic risk factors described above is that they cause BBB disruption (54, 56, 71, 72).”
BackgroundRaimondi, C., Gleichgerrcht, E. L., Richly, P., Torralva, T., Roca, M., Camino, J., & Manes, F. F. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.08.002 · Cited by 20
Coronary artery disease in patients with dementia
Fowkes, R., Byrne, M. H. V., Sinclair, H., Tang, E. Y. H., & Kunadian, V. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000377 · Cited by 22
Imaging of Cerebral Amyloid Angiopathy with Bivalent 99mTc-Hydroxamamide Complexes
Iikuni, S., Ono, M., Watanabe, H., Matsumura, K., Yoshimura, M., Kimura, H., Ishibashi‐Ueda, H., Okamoto, Y., Ihara, M., & Saji, H. (2016) · Scientific Reports · doi:10.1038/srep25990 · Cited by 20
In Vivo Two Photon Imaging of Astrocytic Structure and Function in Alzheimer’s Disease
Kelly, P., Hudry, E., Hou, S. S., & Bacskai, B. J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00219 · Cited by 20
Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran
Grossmann, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094805 · Cited by 20
“Clinical observations further revealed that CAA and AD pathology co-occur in the brain of AD patients with an incidence of 82–98% [68].”
BackgroundRajpoot, J., Crooks, E. J., Irizarry, B. A., Amundson, A., Nostrand, W. E. V., & Smith, S. O. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00781 · Cited by 20
Nascent Lobar Microbleeds and Stroke Recurrences
Imaizumi, T., Inamura, S., Kohama, I., Yoshifuji, K., Nomura, T., & Komatsu, K. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.05.011 · Cited by 18
Cardiovascular risk factors affect hippocampal microvasculature in early AD
Schwartz, E., Wicinski, B. A., Schmeidler, J., Haroutunian, V. H., & Hof, P. R. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0040-9 · Cited by 19
“Multiple studies have in fact shown that the presence of cerebrovascular lesions may participate in determining dementia severity by causing a worsening of clinical symptoms at lower levels of AD pathology [60-63], which could account for the breakdown of the correlation in groups with both AD and a risk factor.”
Clinical Syndromes and Management of Intracerebral Hemorrhage
Ko, S., Choi, H. A., & Lee, K. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0251-2 · Cited by 20
Risk factors for recurrent cerebral amyloid angiopathy-related intracerebral hemorrhage
Jia, X., Bo, M., Zhao, H., Xu, J., Pan, L., & Lu, Z. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1265693 · Cited by 18
“Among the various phenotypes of CAA, spontaneous intracerebral hemorrhage (ICH) is one of the most widely studied, accounting for approximately 5–20% of spontaneous ICH in the elderly (3).”
BackgroundVollhardt, A., Frölich, L., Stockbauer, A., Danek, A., Schmitz, C., & Wahl, A.-S. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106845 · Cited by 19
“Furthermore, CAA causes not only hemorrhages, including microbleeds, but also capillary occlusion and blood flow disturbances leading to infarcts and white matter lesions resulting from hypoperfusion and dysfunctional vascular autoregulation (Thal et al., 2012; Jellinger, 2002; Attems et al., 2011; Yamada and Naiki, 2…”
InfluentialChronic cerebral hypoperfusion and dementia
Yata, K., & Tomimoto, H. (2014) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.124 · Cited by 19
Rocchi, A., Valensin, D., Aldinucci, C., Giani, G., Barbucci, R., Gaggelli, E., Kozłowski, H., & Valensin, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.08.021 · Cited by 20
Park, Y. S., Chung, M. S., & Choi, B. (2019) · Yonsei Medical Journal · doi:10.3349/ymj.2019.60.8.774 · Cited by 18
Kuroda, T., Honma, M., Mori, Y., Futamura, A., Sugimoto, A., Yano, S., Kinno, R., Murakami, H., & Ono, K. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00013 · Cited by 19
“CAA and hypertensive microangiopathy (HM) are major pathological mechanisms for cerebral microbleeds (CMB) in AD (Jellinger, 2002; Hanyu et al., 2003; Cordonnier et al., 2006; Yamada, 2015).”
BackgroundSkoog, I. G., Kern, S., Zetterberg, H., Östling, S., Börjesson‐Hanson, A., Guo, X., & Blennow, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170950 · Cited by 20
“WMLs have been shown to aggravate clinical symptoms of AD [27].”
BackgroundMouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Skaaraas, G. H. E. S., Melbye, C., Puchades, M. A., Leung, D. S. Y., Jacobsen, Ø., Rao, S. B., Ottersen, O. P., Leergaard, T. B., & Torp, R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210571 · Cited by 17
“Cerebral amyloid angiopathy (CAA), characterized by accumulation of A around cerebral blood vessels, is reported in approximately 90% of AD patients [11, 12].”
Neurovascular coupling in early stage dementia – A case-control study
van Dijk, S. E., Drenth, N., Hafkemeijer, A., Labadie, G., Witjes‐Ané, M. W., Blauw, G. J., Rombouts, S. A. R. B., van der Grond, J., & van Rooden, S. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231214102 · Cited by 17
Chong, J. R., Chai, Y. L., Yam, T. Y. A., Hilal, S., Vrooman, H. A., Venketasubramanian, N., Blennow, K., Zetterberg, H., Ashton, N. J., Chen, C., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12576 · Cited by 27
Marín-Castañeda, L. A., González-Garibay, G., Garcia-Quintana, I., Aispuro, G. P., & Rubio, C. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1494356 · Cited by 18
Scott, T. M., Bhadelia, R. A., Qiu, W. Q., Folstein, M. F., & Rosenberg, I. H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180366 · Cited by 18
Xia, M., Su, Y., Fu, J., Xu, J., Wang, Q., Gao, F., Shen, Y., Dong, Q., & Cheng, X. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210288 · Cited by 16
Faakye, J., Nyúl‐Tóth, Á., Gulej, R., Csík, B., Tarantini, S., Shanmugarama, S., Prodan, C. I., Mukli, P., Yabluchanskiy, A., Conley, S. M., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00839-w · Cited by 16
Gao, B.-B., Long, Z., Zhao, L., & He, G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110308 · Cited by 15
“Recent studies suggest that AD is a microvascular and synergistically to cognitive decline related to AD pathology [10].”
Fine Mapping of the Amyloid β-Protein Binding Site on Myelin Basic Protein
Kotarba, A. E., Aucoin, D., Hoos, M. D., Smith, S. O., & Nostrand, W. E. V. (2013) · Biochemistry · doi:10.1021/bi4001936 · Cited by 17
Plaschke, K., Sommer, C., Fahrner, A., Amann, K., Martin, E., Bardenheuer, H. J., & Knauth, M. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0830-z · Cited by 15
“Later, detailed light and electron microscopic examinations of the cerebral blood vessels disclosed a variety of morphometric and morphological alterations in microvasculature in various brain regions of aged rats, ageing humans and dementia (Hunziker et al., 1979; Mancardi et al., 1980; Bell and Ball, 1986; Hanyu et…”
BackgroundAD Vaccines: Conclusions and Future Directions
Wisniewski, T. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847289 · Cited by 14
“Furthermore CAA is present in about 33% of cognitively normal elderly, control populations [57].”
BackgroundInfluentialProgressive mechanical and structural changes in anterior cerebral arteries with Alzheimer’s disease
Liu, X., Halvorsen, S., Blanke, N., Downs, M. J., Stein, T. D., Bigio, I. J., Zaia, J., & Zhang, Y. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01331-5 · Cited by 18
“Alzheimer’s disease (AD), a neurodegenerative disease characterized by the appearance of neurofibrillary tangles and accumulation of amyloid-β (Aβ) peptide in the brain [24, 40], is the most prevalent cause of dementia [1].”
BackgroundSalian, V. S., Tang, X., Thompson, K. J., Curran, G. L., Lowe, V. J., Li, L., Kalari, K. R., & Kandimalla, K. K. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002280 · Cited by 18
Doi, H., Inamizu, S., Saitoh, B., Murai, H., Araki, T., & Kira, J. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3747 · Cited by 16
Kulesh, A. A., Евгеньевич, Д. В., & Shestakov, V. V. (2018) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2018-3-4-11 · Cited by 14
Snorradóttir, Á. Ó., Ísaksson, H. J., Kaeser, S. A., Skodras, A., Ólafsson, E., Pálsdóttir, Á., & Bragason, B. Þ. (2013) · Brain Research · doi:10.1016/j.brainres.2013.08.029 · Cited by 16
“Sporadic CAA is associated with AD-related pathology and more than 80% of AD patients have CAA (Jellinger, 2002; Jellinger and Attems, 2006).”
BackgroundMichiels, L., Weehaeghe, D. V., Vandenberghe, R. R., Demeestere, J., Laere, K. V., & Lemmens, R. (2021) · Cerebrovascular Diseases · doi:10.1159/000514139 · Cited by 14
van Dijk, S. E., van der Grond, J., Lak, J., van den Berg-Huysmans, A., Labadie, G., Terwindt, G. M., Wermer, M. J. H., Gurol, M. E., van Buchem, M. A., Greenberg, S. M., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.035826 · Cited by 14
Webster, J. M., Yang, Y.-T., Miller, A. T., Zane, A., Scholz, K., Stone, W. J., Mudium, N., Corbin-Stein, N. J., Won, W.-J., Stoll, A. C., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107323 · Cited by 15
Histopathological Analysis of Cerebrovascular Lesions Associated With Aging
Dallaire‐Théroux, C., Saïkali, S., Richer, M., Potvin, O., & Duchesne, S. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab125 · Cited by 17
Serum Brevican as a Biomarker of Cerebrovascular Disease in an Elderly Cognitively Impaired Cohort
Chia, R. S. L., Minta, K., Wu, L., Salai, K. H. T., Chai, Y. L., Hilal, S., Venketasubramanian, N., Chen, C., Chong, J. R., & Lai, M. K. P. (2024) · Biomolecules · doi:10.3390/biom14010075 · Cited by 15
Zhang, Q., Coury, R., & Tang, W. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01421-y · Cited by 17
“The association between brain injury or brain lesions and AD has been well-documented in the literature [28, 29].”
BackgroundLaslo, A., Laslo, L., Arbănași, E. M., Ujlaki-Nagi, A.-A., Chinezu, L., Ivănescu, A. D., Arbănași, E. M., Carare, R. O., Cordoș, B. A., Popa, I. A., et al. (2024) · Pathophysiology · doi:10.3390/pathophysiology31040040 · Cited by 15
“…CSF amyloid status, have been associated with a higher atrophy rate of the entorhinal cortex in cognitively normal patients, patients with mild cognitive impairment, and patients with AD, suggesting that CLU may play a role in the earliest stages of the neurodegenerative process of AD [6,32,33].”
BackgroundBrommelhoff, J. A., & Sultzer, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-148007 · Cited by 14
Vascular Considerations for Amyloid Immunotherapy
Foley, K. E., & Wilcock, D. M. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01235-1 · Cited by 17
Imaizumi, T., Inamura, S., & Nomura, T. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.04.027 · Cited by 13
Mairuae, N., Hall, E. C., II, Cheepsunthorn, P., Lee, S. Y., & Connor, J. R. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22466 · Cited by 13
Cognition in Vascular Aging and Mild Cognitive Impairment
Tsentidou, G., Μoraitou, D., & Tsolaki, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190638 · Cited by 13
“MRI evidence of white matter alteration is one of the several subtypes of vascular pathologies associated with dementia [120, 121].”
Hereditary and sporadic beta-amyloidoses
Fede, G. D., Giaccone, G., & Tagliavini, F. (2013) · Frontiers in bioscience · doi:10.2741/4173 · Cited by 15
Kimura, A., Takemura, M., Saito, K., Yoshikura, N., Hayashi, Y., Harada, N., Nishida, H., Nakajima, H., & Inuzuka, T. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8362-2 · Cited by 14
Singh, P. K., Chen, Z., Strickland, S., & Norris, E. H. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200343 · Cited by 14
“Cerebral amyloid angiopathy (CAA), or the deposition of the pathogenic amyloid(A ) protein in and around blood vessels, is a vascular abnormality present in 80–95% of AD patients [3].”
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 13
A modern concept of mixed dementia
Bogolepova, A. N. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201511551120-126 · Cited by 13
Sheikh‐Bahaei, N., Manavaki, R., Sajjadi, S. A., Priest, A. N., O'Brien, J. T., & Gillard, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180443 · Cited by 13
Chen, H., & Zhang, J. H. (2011) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-0693-8_3 · Cited by 12
“111, 15 DOI: 10.1007/978-3-7091-0693-8_3, © Springer-Verlag/Wien 2011 Abstract There is a growing understanding of cerebral amyloid angiopathy (CAA), which accounts for the majority of primary lobal intracerebral hemorrhages (ICH) among the elderly [1] and is cited as the cause of 20% of spontaneous ICHs in patients o…”
BackgroundInfluentialRangel, A., Race, B., Striebel, J. M., & Chesebro, B. W. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01303.x · Cited by 12
Direct oral anticoagulants: a new therapy against Alzheimer’s disease?
Grossmann, K. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303029 · Cited by 14
“In clinical studies, CAA and AD pathology co-occur in the same brain with an incidence of 82–98% (Jellinger, 2002).”
BackgroundInfluentialTheodorou, A., Palaiodimou, L., Papagiannopoulou, G., Kargiotis, O., Psychogios, K., Safouris, A., Bakola, E., Chondrogianni, M. E., Kotsali-Peteinelli, V., Melanis, K., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175591 · Cited by 11
“CAA is a disease of the elderly with a prevalence of 50–60% among demented elderly populations and a prevalence of 85–95% among patients with Alzheimer’s disease [2,3].”
BackgroundGaur, A., Gallagher, D., Herrmann, N., Chen, J. J., Marzolini, S., OH, P. I., Amemiya, Y., Seth, A. K., Kiss, A., & Lanctôt, K. L. (2024) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887241254469 · Cited by 12
Molecular cloning and characterization of the promoter region of the porcine apolipoprotein E gene
Xia, J., Hu, B., Mu, Y., Xin, L., Yang, S., & Li, K. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3182-x · Cited by 11
“three alleles E2, E3 and E4, for six phenotypes [7].”
BackgroundBackground and distribution of lobar microbleeds in cognitive dysfunction
Matsuyama, H., Ii, Y., Maeda, M., Umino, M., Ueda, Y., Tabei, K., Kida, H., Satoh, M., Shindo, A., Taniguchi, A., et al. (2017) · Brain and Behavior · doi:10.1002/brb3.856 · Cited by 12
“Autopsy studies have revealed that around 90% of AD cases are associated with CAA pathology of varying severity (Jellinger, 2002), and therefore, lobar CMBs in patients with AD are thought to be TABLE 3 Comparison of “lobar” CMB- positive cases:SL- CMBs versus M- CMBs CMBs type SL- CMBs M- CMBs p-…”
BackgroundMRI Markers of Small Vessel Disease and the APOE Allele in Cognitive Impairment
Shams, M., Shams, S., Martola, J., Cavallin, L., Granberg, T., Kaijser, M., Wintermark, M., Westman, E., Aspelin, P., Wiberg, M. K., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.897674 · Cited by 14
“MRI markers of SVD have shown to be especially prevalent in patients with vascular dementia and AD, and in AD, almost all patients are thought to suffer from cerebral amyloid angiopathy (Jellinger, 2002; Smith and Greenberg, 2009; Shams et al., 2014).”
BackgroundRegional cortical blood flow changes following sodium lactate infusion in Alzheimer's disease
Kalman, J. L., Palotás, A., Kis, G., Boda, K., Túri, P., Bari, F., Domoki, F., Dóda, I., Árgyelán, M., Vincze, G., et al. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03924.x · Cited by 13
“thickening of the endothelial basal membrane (Farkas et al., 2002) and disruption of the blood–brain barrier (BBB), were found in AD brains ( Jellinger, 2002 ).”
BackgroundSong, J., Peng, X., Li, L., Yang, F., Zhang, X., Zhang, J., Dai, J., & Cui, M. (2018) · ACS Omega · doi:10.1021/acsomega.8b01120 · Cited by 13
Gregory, J. L., Prada, C. M., Fine, S., García-Alloza, M., Betensky, R. A., Arbel‐Ornath, M., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182729845 · Cited by 11
“Cerebral amyloid angiopathy (CAA) is an age-related disease found in Alzheimer disease (AD) patients and in the normal aging population (1).”
Ortega, G., Espinosa, A., Alegret, M., Monté, G. C., Sotolongo‐Grau, Ó., Sanabria, Á., Tartari, J. P., Rodríguez‐Gómez, O., Marquié, M., Vivas, A., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00877-6 · Cited by 11
Models of cerebral amyloid angiopathy-related intracerebral hemorrhage
Vargas-George, S. A., & Dave, K. R. (2022) · Brain Hemorrhages · doi:10.1016/j.hest.2022.05.001 · Cited by 11
The Neuropathologic Substrates of Vascular-Ischemic Dementia
Jellinger, K. A. (2005) · Humana Press eBooks · doi:10.1385/1-59259-824-2:023 · Cited by 11
Self-citationZhang, Y., Chao, F., Zhang, L., Jiang, L. H., Zhou, C., Chen, L., Lü, W., Jiang, R., & Tang, Y. C. (2019) · Brain and Behavior · doi:10.1002/brb3.1268 · Cited by 14
68 Ga-Labeled Benzothiazole Derivatives for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy
Huynh, T. T., Wang, Y., Terpstra, K., Cho, H., Mirica, L. M., & Rogers, B. E. (2022) · ACS Omega · doi:10.1021/acsomega.2c02369 · Cited by 10
Cerebral Amyloid Angiopathy with Severe Secondary Vascular Pathology: A Histopathological Study
van Horssen, J., de Jong, D., de Waal, R. M. W., Maass, C., Otte‐Höller, I., Kremer, B. P. H., Verbeek, M. M., & Wesseling, P. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000088462 · Cited by 12
“Cerebral amyloid angiopathy (CAA) is a common finding in the aging brain. It is observed in 80–90p of patients with neuropathologically confirmed Alzheimer’s disease (AD), in 15–20p of patients who present with lobar hemorrhages, as well as in elderly patients with small cortical infarcts or punctate cortical hemorrha…”
BackgroundCognitive Function in Atrial Fibrillation: A Narrative Review of Evidence and Mechanisms
Agarwal, R., Tully, P. J., & Mahajan, R. (2024) · Heart and Mind · doi:10.4103/hm.hm-d-23-00075 · Cited by 12
Impact of APOE on cerebrovascular lipid profile in Alzheimer’s disease
Inoue, Y., Wang, H., Heckman, M. G., Ren, Y., White, L. J., Lü, W., Wang, P., Julia, T. C. W., Koga, S., Alnobani, A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02949-5 · Cited by 10
“CAA occurs in more than 90% of patients with AD [36].”
Cell ageing: a flourishing field for neurodegenerative diseases
Brites, D. M. T. O. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.3.225 · Cited by 11
“Although not clarified whether cerebral vascular dysfunction is a cause or a consequence of AD, it has been associated with disease progression and neuroinflammation [45,46].”
BackgroundAnderson, M. E., Xu, F., Ou-Yang, M.-H., Davis, J., Nostrand, W. E. V., & Robinson, J. K. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160674 · Cited by 9
Nakano, Y., Deguchi, K., Yamashita, T., Morihara, R., Matsuzono, K., Kawahara, Y., Sato, K., Kono, S., Hishikawa, N., Ohta, Y., et al. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.03.037 · Cited by 10
“A clinical study also suggested an agedependent increase of amyloid angiopathy, which is a common cause of stroke and is found in about 90% of AD cases.(31,32) A simple comparison between reverters and converters suggests risks of conversion for older age, CE, more severe WMH, HT, and a greater number of MBs (Fig 3).”
BackgroundThe effect of old age on apolipoprotein E and its receptors in rat liver
Sabaretnam, T., O'Reilly, J. N., Kritharides, L., & Couteur, D. G. L. (2009) · AGE · doi:10.1007/s11357-009-9115-2 · Cited by 9
“ApoE alleles (ε2, ε3, ε4) are linked with agerelated diseases such as Alzheimer’s disease and cardiovascular disease and contribute to the genetic component of longevity (Ang et al. 2008; Jellinger 2002; Smith 2002).”
BackgroundSolé‐Padullés, C., Bartrés‐Faz, D., Junqué, C., Vía, M., Matarín, M., González‐Pérez, E., Moral, P., Moya, A., & Clemente, I. C. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.044 · Cited by 9
Spatial distribution of hemorrhages in cerebral amyloid angiopathy
Jellinger, K. A. (2005) · Annals of Neurology · doi:10.1002/ana.20739 · Cited by 10
“6 years) with spontaneous, nontraumatic ICHs in autopsy-proven Alzheimer’s disease with severe CAA.(2) Most had been demented, with evidence for hypertension in 36%.”
BackgroundSelf-citationChen, G., Zhang, K., Sun, M., Xie, N., Wu, L., Zhang, G., Guo, B., Huang, C., Hoi, M. P. M., Zhang, Z., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110410 · Cited by 9
Cifù, A., Janes, F., Mio, C., Domenis, R., Pessa, M. E., Garbo, R., Curcio, F., Valente, M., & Fabris, M. (2023) · Biomedicines · doi:10.3390/biomedicines11113055 · Cited by 9
“…by its association with several heterogenous disorders, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and rheumatologic diseases; and also with chronic conditions, such as chronic hypoxia, obesity, diabetes, congestive heart failure, and metabolic syndrome [4,5,7–9].”
Backgroundvan Dijk, S. E., Drenth, N., Hafkemeijer, A., Labadie, G., Witjes‐Ané, M. W., Baas, F., Vreijling, J. P., Blauw, G. J., Rombouts, S. A. R. B., van der Grond, J., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038819 · Cited by 9
“12 Additionally, there is evidence of comorbid nonamyloid small vessel disease in AD, 13 sometimes referred to as hypertensive SVD.”
Iikuni, S., Ono, M., Watanabe, H., Yoshimura, M., Ishibashi‐Ueda, H., Ihara, M., & Saji, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163969 · Cited by 9
Parvin, F., Haglund, S., Wegenast‐Braun, B. M., Jucker, M., Saito, T., Saido, T. C., Nilsson, K. P. R., Nilsson, P., Nyström, S., & Hammarström, P. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00104 · Cited by 10
Demência vascular Critérios diagnósticos e exames complementares
Engelhardt, E., Tocque, C., André, C., Moreira, D. M., Okamoto, I. H., & Cavalcanti, J. L. D. S. (2011) · Dementia & Neuropsychologia · Cited by 21
Caspases in Alzheimer’s Disease
Zhang, Y. (2013) · InTech eBooks · doi:10.5772/54627 · Cited by 9
“Besides the main pathology discussed above, some other pathologies of AD include granulovacuolar degeneration, cerebral amyloid angiopathy, blood-brain barrier disorder, white matter lesions, neuropil thread and gliosis (Jellinger, 2002a; Jellinger, 2002b, c; Jellinger and Attems, 2003).”
BackgroundCerebral amyloid angiopathy: a transient ischaemic attack mimic
Illsley, A., & Ramadan, H. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-3-255 · Cited by 12
Angiotensin converting enzyme and Alzheimer’s disease
Kugaevskaya, E. V. (2012) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075081201009x · Cited by 9
Diagnostics and treatment of chronic cerebral ischemia
Zakharov, V. V., Васильевна, В. Н., Gogoleva, A. G., & Mezhmidinova, S. K. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-8-36-45 · Cited by 8
Li, N., Zhang, X., Gu, Z., Su, C., & Lian, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8008 · Cited by 10
“The clinical manifestations of CAA are partially similar to AD, and 80% or more of CAA patients demonstrate AD pathological changes (9).”
BackgroundSabaretnam, T., Kritharides, L., O'Reilly, J. N., & Couteur, D. G. L. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.08.018 · Cited by 8
Ku, H., & Chi, N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.02.032 · Cited by 8
“The presence of CAA may increase the risk of cerebral lobar mass hemorrhage and microhemorrhage [9].”
BackgroundChatterjee, P., Dominantly Inherited Alzheimer Network, Fagan, A. M., Xiong, C., McKay, M. J., Bhatnagar, A., Wu, Y., Singh, A. K., Taddei, K., Martins, I. J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201267 · Cited by 8
“While these observations are in line with the findings of lower spermidine levels in D-CAA MCs seen within the present study given that 80% of AD patients show CAA comorbidity [19], the exact mechanisms are currently not known.”
Brain and retina in Alzheimer's disease: Pathological intersections and estimates from imaging
Banihashemi, M. A., Krance, S. H., Ji, P. X., Koo, M., Ottoy, J., Swartz, R. H., Kertes, P. J., Hudson, C., Goubran, M., & Black, S. E. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70884 · Cited by 9
rTg-D: A novel transgenic rat model of cerebral amyloid angiopathy Type-2
Davis, J., Xu, F., Zhu, X. A., & Nostrand, W. E. V. (2022) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2022.100133 · Cited by 9
“With CAA type-1 fibrillar amyloid deposits engage the surrounding neuropil causing strong perivascular neuroinflammation that is correlated with poorer cognition and dementia in individuals afflicted with AD and in CAA patients [3,5,9,12,13].”
BackgroundMichiels, L., Dobbels, L., Demeestere, J., Demaerel, P., Laere, K. V., & Lemmens, R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103107 · Cited by 7
“…(Lockhart et al., 2007; Johnson et al., 2007; Greenberg et al., 2008; Ly et al., 2010; Gurol et al., 2013; Baron et al., 2014; Gurol et al., 2016; Raposo et al., 2017), two forms of amyloid that typically co-occur (Ellis et al., 1996; Jellinger, 2002; Attems et al., 2007; Charidimou et al., 2015).”
Backgroundα-Enolase reduces cerebrovascular Aβ deposits by protecting Aβ amyloid formation
Inoue, Y., Tasaki, M., Masuda, T., Misumi, Y., Nomura, T., Ando, Y., & Ueda, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04493-x · Cited by 7
“Postmortem studies revealed that CAA occurred in more than 90% of patients with Alzheimer’s disease (AD) [3].”
BackgroundExtracellular vesicles: the key to unlocking mechanisms of age-related vascular disease?
Whitehead, M., Antonazzi, M., & Shanahan, C. M. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.49 · Cited by 7
Functional MRI in Alzheimer’s Disease
Kivistö, J., Soininen, H. S., & Pihlajamaki, M. M. (2014) · InTech eBooks · doi:10.5772/58264 · Cited by 12
“Accordingly, AD can be heterogeneous in terms of genetic background (Bertram et al., 2007), response to treatment (Kaduszkiewicz et al., 2005) as well as neuropathological and neuro‐ radiological patterns (Henry-Feugeas, 2007; Jagust et al., 2008; Jellinger, 2002).”
Background
Metadata
- Authors
- Jellinger, K. A.
- Affiliations
- Ludwig Boltzmann für Klinische Neurobiologie (AT)
- Corresponding author
- Jellinger, K. A.
- ORCID
- Jellinger, K. A.
- Venue
- Journal of Neural Transmission
- Published
- 2002-05-01
- Volume
- 109
- Issue
- 5-6
- Pages
- 813-836
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2084675121
- Cited by
- 680
- References
- 114
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 32 · 2023: 19 · 2022: 38 · 2021: 32 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 22 · 2016: 30 · 2015: 44 · 2014: 38 · 2013: 27 · 2012: 39
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, cerebrovascular pathology, cerebral amyloid angiopathy, cerebral hemorrhage, microinfarcts, lacunes, white matter lesions, mixed dementia, vascular dementia, cognitive decline, dementia progression, blood-brain barrier dysfunction
- MeSH terms
- Alzheimer Disease, Blood Vessels, Cerebrovascular Circulation, Cerebrovascular Disorders, Diagnosis, Differential, Humans, Microcirculation, Risk Factors, Dementia, Vascular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.